Skip to main content

The Need of New Drug for Tuberculosis (Need of RtmB Inhibitors to Back Aminoglycoside in Market)

Pharma courses

 

GPAT courses

 

pharma courses

 

GPAT courses

 


Submitted by admin on 1 December 2012


TB bacteria have developed many different ways to protect themselves from attack by aminoglycoside and other antibiotics.

Ribosomal RNA methyl transferase B (RmtB) is one of the new enzyme developed by TB bacteria to make the modification in 16 s rRNA in 30s ribosomal subunit (target of aminoglycoside).

So, Inhibition of this new developed enzyme (RmtB) is therefore an important challenge for the development of a new effective therapy for tuberculosis

Record your opinion on the above link.

Search this website